Gilead Sciences (GILD) EBIT (QoQ) (2009 - 2026)
Gilead Sciences (GILD) EBIT (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.34% |
| Dec 31, 2025 | -40.37% |
| Sep 30, 2025 | 34.48% |
| Jun 30, 2025 | 10.59% |
| Mar 31, 2025 | -8.77% |
| Dec 31, 2024 | 176.13% |
| Sep 30, 2024 | -66.41% |
| Jun 30, 2024 | 161.18% |
| Mar 31, 2024 | -368.11% |
| Dec 31, 2023 | -38.54% |
| Sep 30, 2023 | 57.54% |
| Jun 30, 2023 | -2.35% |
| Mar 31, 2023 | -24.79% |
| Dec 31, 2022 | -20.09% |
| Sep 30, 2022 | 39.82% |
| Jun 30, 2022 | 929.95% |
| Mar 31, 2022 | -79.04% |
| Dec 31, 2021 | -75.53% |
| Sep 30, 2021 | 71.06% |
| Jun 30, 2021 | -22.28% |